" class="no-js "lang="en-US"> Kirk Nielsen - Medtech Alert
Saturday, October 18, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Kirk Nielsen

Kirk Nielsen

About Kirk Nielsen

Kirk Nielsen is a Minneapolis-based Managing Partner at Vensana Capital, a medtech-focused venture capital and growth equity firm launched with the support of Versant. At Versant, Kirk led or co-led investments into Cameron Health (sale), CardiAQ (sale), Ceterix Orthopaedics (sale), Lutonix (sale), NeuWave Medical (sale), Sequent Medical (sale), Zyga Technology (sale), Inari Medical, Metavention, Monteris Medical, Nuvaira, Respicardia, and Veran Medical.

Related Story

Fundraising

 Vensana Capital Raises $325 Million and Expands Team to Back Transformative Medical Technology Innovations | Pharmtech Focus

Vensana Capital Raises $325 Million and Expands Team to Back Transformative Medical Technology Innovations

September 30 2021

Vensana Capital today announced the closing of its second fund, Vensana Capital II, with $325 million […]